EMPLOYMENT AGREEMENTEmployment Agreement • November 19th, 2021 • Vigil Neuroscience, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Vigil Neuroscience, Inc., a Delaware corporation (the “Company”), and ___________________ (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated ______ (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
LEASE From 100 FORGE HOLDING LLC, Landlord To VIGIL NEUROSCIENCE, INC., Tenant 100 Forge Road, Watertown, MassachusettsLease • November 19th, 2021 • Vigil Neuroscience, Inc. • Biological products, (no disgnostic substances) • Massachusetts
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and VIGIL NEUROSCIENCE, INC. Dated as of July 9, 2020Exclusive License Agreement • November 19th, 2021 • Vigil Neuroscience, Inc. • Biological products, (no disgnostic substances) • New York
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of July 9, 2020 (the “Effective Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“AMGEN”), and VIGIL NEUROSCIENCE, INC., a Delaware corporation having an address at 400 Technology Square, 10th Floor, Cambridge, MA 02139 (“VIGIL”). VIGIL and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SERVICE AGREEMENTService Agreement • November 19th, 2021 • Vigil Neuroscience, Inc. • Biological products, (no disgnostic substances) • Massachusetts
The licensee(s) identified on the signature block of this agreement (the “Licensee”) and CIC hereby agree to the following (the “Agreement” or “Service Agreement”).
November 4, 2021 PERSONAL AND CONFIDENTIAL Richard A. Fisher, PhD Re: Transition Agreement Dear Richard:Vigil Neuroscience, Inc. • November 19th, 2021 • Biological products, (no disgnostic substances) • Massachusetts
As discussed, we greatly appreciate your service and contributions to Vigil Neuroscience, Inc. (the “Company”), as well as your commitment to a smooth transition for the Company during this critical time. This letter agreement (the “Transition Agreement”) summarizes your transition into an advisory role with the Company during the remainder of your employment as well as the opportunity for you to continue as a consultant for the Company after your separation from employment. As set forth further below, this Transition Agreement will supersede your employment agreement with the Company, dated August 15, 2020 (the “Employment Agreement”), except to the extent provisions are specifically preserved and incorporated herein.
